Nipro Diagnostics and NeuroMetrix Announce Diabetes Focused Collaboration for the Retail Medical Clinic Market
Nipro Diagnostics, Inc. and NeuroMetrix, Inc. (Nasdaq: NURO) today announced their collaboration to evaluate opportunities for NC-stat | DPNCheck in retail medical clinics. NC-stat DPNCheck is a rapid, quantitative, point-of-care test for the evaluation of systemic neuropathies such as diabetic peripheral neuropathy.
DPN affects more than half of people with diabetes and may lead to foot ulcers and limb amputation, as well as pain and an overall reduction in quality of life. Nipro and NeuroMetrix believe that this test may address the unmet medical need for better and cost-effective approaches to detecting and monitoring DPN.
© 2017 Benzinga.com. Benzinga does not provide investment advice. All rights reserved.